APGE APOGEE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, APOGEE THERAPEUTICS INC reported revenue of n/a, net income of −$85.9M and diluted EPS of −$1.14; for the fiscal year ended December 2025 revenue was n/a.
APGE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$286M, net income −$256M (margin n/a), EPS −$4.22
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$217M, net income −$182M (margin n/a), EPS −$3.30
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$93.0M, net income −$84.0M (margin n/a), EPS −$3.36
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$30.7M, net income −$39.8M (margin n/a), EPS −$16.16
APGE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$85.9M, EPS −$1.14
- Quarter ended Mar 31, 2026: revenue n/a, net income −$74.1M, EPS −$1.06
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$69.4M, EPS −$1.03
- Quarter ended Sep 30, 2025: revenue n/a, net income −$65.0M, EPS −$1.11
- Quarter ended Jun 30, 2025: revenue n/a, net income −$66.1M, EPS −$1.13
- Quarter ended Mar 31, 2025: revenue n/a, net income −$55.3M, EPS −$0.95
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$67.2M, EPS −$1.20
- Quarter ended Sep 30, 2024: revenue n/a, net income −$49.0M, EPS −$0.86
- Quarter ended Jun 30, 2024: revenue n/a, net income −$33.8M, EPS −$0.60
- Quarter ended Mar 31, 2024: revenue n/a, net income −$32.1M, EPS −$0.64
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$31.7M, EPS $3.44
- Quarter ended Sep 30, 2023: revenue n/a, net income −$20.8M, EPS −$0.51
- Quarter ended Jun 30, 2023: revenue n/a, net income −$18.9M, EPS −$3.78
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.5M, EPS −$2.51
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$14.0M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$19.7M, EPS −$9.46
- Quarter ended Jun 30, 2022: revenue n/a, net income −$1.82M, EPS −$1.45
- Quarter ended Mar 31, 2022: revenue n/a, net income −$4.31M, EPS n/a
APGE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$227M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$171M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$74.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$16.4M, share buybacks n/a
APGE balance sheet
- Jun 30, 2026: cash $106M, total assets $1.34B, total liabilities $141M, shareholders' equity n/a
- Mar 31, 2026: cash $452M, total assets $1.29B, total liabilities $37.9M, shareholders' equity n/a
- Dec 31, 2025: cash $132M, total assets $937M, total liabilities $33.3M, shareholders' equity n/a
- Sep 30, 2025: cash $108M, total assets $626M, total liabilities $39.8M, shareholders' equity n/a
- Jun 30, 2025: cash $124M, total assets $658M, total liabilities $38.4M, shareholders' equity n/a
- Mar 31, 2025: cash $107M, total assets $714M, total liabilities $40.8M, shareholders' equity n/a
- Dec 31, 2024: cash $142M, total assets $754M, total liabilities $37.2M, shareholders' equity n/a
- Sep 30, 2024: cash $119M, total assets $776M, total liabilities $41.9M, shareholders' equity n/a
Is APGE profitable?
No. APOGEE THERAPEUTICS INC lost $294M over the last four quarters.
What is APGE's EPS?
Diluted earnings per share over the last four quarters were −$4.34; −$1.14 in the latest quarter.